Back to search

Article

Super-enhancer-driven HAVCR1 defines cisplatin resistance yet immunotherapy responsiveness in non-small-cell lung cancer

2026-04-24

Abstract excerpt

<title>Abstract</title> <p> Cisplatin (DDP) resistance remains a major obstacle in the treatment of non-small-cell lung cancer (NSCLC), underscoring the need to identify robust prognostic biomarkers and therapeutic strategies. Super-enhancers (SEs) play central roles in orchestrating oncogenic transcriptional programs and cellular adaptation to therapeutic stress. In this study, we integrated H3K27ac ChIP-seq an...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
cd06ad24-4860-5ca4-9c0c-e5e9a188b2a1
DOI
10.21203/rs.3.rs-9304377/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Super-enhancer-driven HAVCR1 defines cisplatin resistance yet immunotherapy responsiveness in non-small-cell lung cancerDOI 10.21203/rs.3.rs-9304377/v1
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.Semantic proximity
PSMB5-centered immunotherapy resistance signature predicts prognosis and drives CD8+ T cell exclusion in lung adenocarcinomaSemantic proximity
Super-enhancer MYCNOS-SE promotes chemoresistance in small cell lung cancer by recruiting transcription factors CTCF and KLF15Semantic proximity
Corrigendum to: Effects of SVEP1 on Lung Squamous Cell Carcinoma and its Association with Tumor Mutation Burden, Prognosis, and Immune Regulation.Semantic proximity
Integrative Analysis of Checkpoint Blockade Response in Advanced Non-Small Cell Lung CancerSemantic proximity
Identification and experimental verification of a novel cisplatin resistance-related lncRNA signature for predicting prognosis and immune response in lung adenocarcinoma.Semantic proximity
Super-enhancer-driven ITGA6 enhances stemness features of squamous cell carcinoma through stabilizing c-myc proteinSemantic proximity
ETS1 Orchestrates a Hybrid EMT Program Driving in vivo Metastasis and Immune EvasionSemantic proximity
DNA damage response signatures are associated with frontline chemotherapy response and routes of tumor evolution in extensive stage small cell lung cancerSemantic proximity
Regulation of cisplatin resistance in lung cancer by epigenetic mechanismsSemantic proximity
Genetic drivers of tumor microenvironment and immunotherapy resistance in non-small cell lung cancer: the role of KEAP1 , SMARCA4 , and PTEN mutationsSemantic proximity
Targeting DNA Damage Response-Mediated Resistance in Non-Small Cell Lung Cancer: From Mechanistic Insights to Drug DevelopmentSemantic proximity
Select a neighboring publication to make it the new centre.